Your browser doesn't support javascript.
loading
Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
Ergun, Tulin; Hosgoren Tekin, Selcen; Apti Sengun, Ozlem; Akin Cakici, Ozlem; Seckin, Dilek; Adiay, Cumhur; Enul, Hakan; Yilmaz, Seval; Ay, Pinar; Haklar, Goncagul; Sili, Uluhan.
Afiliación
  • Ergun T; Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey. Electronic address: tulin@marmara.edu.tr.
  • Hosgoren Tekin S; Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey.
  • Apti Sengun O; Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey.
  • Akin Cakici O; Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey.
  • Seckin D; Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey.
  • Adiay C; Pendik Veterinary Control Institute, Istanbul, Turkey.
  • Enul H; Pendik Veterinary Control Institute, Istanbul, Turkey.
  • Yilmaz S; Marmara University, School of Medicine, Department of Biochemistry, Istanbul, Turkey.
  • Ay P; Marmara University, School of Medicine, Department of Public Health, Istanbul, Turkey.
  • Haklar G; Marmara University, School of Medicine, Department of Biochemistry, Istanbul, Turkey.
  • Sili U; Marmara University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
Vaccine ; 41(29): 4287-4294, 2023 06 29.
Article en En | MEDLINE | ID: mdl-37277251
BACKGROUND AND OBJECTIVES: Evidence of immune response to COVID-19 vaccine in psoriasis patients on biological agents is lacking. This study aimed to evaluate SARS-CoV-2 antibody levels following vaccination with CoronaVac or Pfizer/BioNTech mRNA in patients using biological agents or methotrexate, high-titer antibody levels achievement rate, and impact of medications on immunogenicity. METHODS: This noninterventional, prospective cohort study included 89 patients and 40 controls vaccinated with two doses of inactivated (CoronaVac) or Pfizer/BioNTech mRNA vaccines. Anti-spike and neutralising antibodies were analysed before and three to six weeks after the second dose. Adverse effects and symptomatic COVID-19 were assessed. RESULTS: Median anti-spike and neutralising antibody titers after CoronaVac were significantly lower in patients than controls (57.92 U/mL vs 125.4 U/mL, and 1/6 vs 1/32, respectively, p < 0.05). Patients were less likely to achieve high-titer anti-spike antibody levels (25.6 % vs 50 %). Infliximab was associated with attenuated vaccine response. Pfizer/BioNTech vaccine induced comparable median anti-spike (2,080 U/mL vs 2,976.5 U/mL,) and neutralising antibody levels (1/96 vs 1/160) in patients and controls, respectively (p > 0.05). High-titer anti-spike and neutralising antibodies development rates were comparable among patients and controls (95.2 % vs 100 %, and 30.4 % vs 50.0 %, respectively, p > 0.05). Nine (10.1 %) COVID-19 cases- all mild - were identified. Psoriasis flare was seen in 6.74 %, mostly after Pfizer/BioNTech vaccine. CONCLUSION: Psoriasis patients treated with biological agents and methotrexate developed similar response to mRNA vaccine but weaker response to inactivated vaccine. Infliximab reduced response to the inactivated vaccine. Adverse effects were more frequent with mRNA vaccine, but none was severe.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos